The Chicago Entrepreneur

Wave Life Sciences’ stock soars 51% after biotech posts positive data from Duchenne muscular-dystrophy trial

Biotech reported positive interim data from a mid-stage trial of a treatment for the rare muscle disorder Duchenne muscular dystrophy.

Previous post As Visa’s stock drops, here’s why a possible antitrust case could be so worrying
Next post Buy this REIT’s stock to make money on the rapid aging of America’s population